Venetoclax in clinical studies
- Authors: Byalik T.E.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: No 12 (2018)
- Pages: 81-84
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295834
- DOI: https://doi.org/10.18565/pharmateca.2018.12.81-84
- ID: 295834
Cite item
Open Access
Access granted
Abstract
Venetoclax is a low-molecular selective inhibitor of the BCL-2 protein. The drug is highly effective in the treatment of various oncohematological diseases. The review presents the data of significant clinical studies on the efficacy and safety of venetoclax. Currently, randomized phase III trials are being conducted to evaluate combinations of VEN with various antitumor drugs for many diseases of the hematopoietic and lymphoid tissues, and perhaps after receiving the results, approaches to the treatment of these diseases will be changed.
Full Text
About the authors
Tatyana E. Byalik
Sechenov First Moscow State Medical University (Sechenov University)
Email: bialik@bk.ru
Teaching Assistant at the Department of Oncology
References
- Seymour J.F., Davids M.S., Pagel J.M., et al. Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti- Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). Blood 2013;122:872.
- Roberts A.W., Davids M.S., Pagel J.M., et al. S1146; EHA; Stockholm. 2013;13-6.
- Stilgenbauer S., Eichhorst B., Schetelig J., et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet. Oncol. 2016;17:768-78. doi: 10.1016/S1470-2045(16)30019-5.
- Stilgenbauer S., Eichhorst B., Schetelig J., et al. Venetoclax for PatientsWith Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J. Clin. Oncol. 2018;36:1-8. doi: 10.1200/JCO.2017. 76.6840
- Jones J., Choi M.Y., Mato A.R., et al. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. Blood. 2016;128:abstract 637.
- Jones J.A., Mato A.R., Wierda W.G., et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;65-75. doi: 10.1016/S1470-2045(17)30909-9.
- AbbVie. Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation in Relapsed or Refractory Chronic Lymphocytic Leukemia in Previously Treated Patients with the 17p Deletion Genetic Mutation [press release].
- Eichhorst B., Robak T., Montserrat P., et al. Chronic Lymphocytic Leukaemia Treatment Recommendations, Published: 27 June 2017. Authors: ESMO Guidelines Committee, Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015;26(5): 78-84.
- Seymour J.F., et al. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. 59TH Annual meeting and exposition of the american society of hematology. Blood 2017;130:LBA-2.
- AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia [press release]. AbbVie. 2018.
- Touzeau C., Dousset C., Le Gouill S., et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210-12. doi: 10.1038/leu.2013.216.
- Kumar S., Kaufman J.L., Gasparetto C., et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401 409. doi: 10.1182/blood-2017-06-788786
- Moreau P, Chanan-Khan A., Roberts A.W., et al. Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. Blood. 2016;128:975. doi: 10.1182/blood-2017-06-788323.
- Pan R., Hogdal L.J., Benito J.M., et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell. death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362-75. doi: 10.1158/2159-8290. CD-13-0609.
- Konopleva M., Pollyea D.A., Potluri J., et al. Efficacy and Biological Correlates of Response in a Phase 2 Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016;6(10):1106-17.
- DiNardo C.D., Pratz K.W., Letai A., et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216-28. doi: 10.1016/S1470-2045(18)30010-X.
- Wei A., Strickland S.A., Roboz G.J., et al. Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcome. Blood. 2017;130:890.
Supplementary files
